{"disease":{"id":"tachycardia","name":"Tachycardia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":13},"drugs":{"marketed":[{"drug_id":"verapamil-hydrochloride","indication_name":"Prophylaxis of paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"flecainide","indication_name":"Paroxysmal Supraventricular Tachycardias (PSVT)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"esmolol","indication_name":"Control of ventricular rate in supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brevibloc In Plastic Container","generic_name":"ESMOLOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":63,"revenue":null,"mechanism":"Brevibloc works by blocking the beta-1 adrenergic receptor, which reduces the heart's response to stress and increases heart rate."},{"drug_id":"esmolol","indication_name":"Control of heart rate in noncompensatory sinus tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brevibloc In Plastic Container","generic_name":"ESMOLOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":63,"revenue":null,"mechanism":"Brevibloc works by blocking the beta-1 adrenergic receptor, which reduces the heart's response to stress and increases heart rate."},{"drug_id":"esmolol","indication_name":"Control of perioperative tachycardia and hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brevibloc In Plastic Container","generic_name":"ESMOLOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":63,"revenue":null,"mechanism":"Brevibloc works by blocking the beta-1 adrenergic receptor, which reduces the heart's response to stress and increases heart rate."},{"drug_id":"flecainide-acetate","indication_name":"Paroxysmal Supraventricular Tachycardias (PSVT)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLECAINIDE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"bretylium","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bretylium Tosylate","generic_name":"BRETYLIUM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"bretylium","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"amiodarone","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cordarone","generic_name":"AMIODARONE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"sodium channels, potassium channels, calcium channels","drug_class":"Antiarrhythmic","quality_score":69,"revenue":null,"mechanism":"Amiodarone, a class III antiarrhythmic, blocks sodium, potassium, and calcium channels, prolongs cardiac action potentials, and has vasodilatory effects."},{"drug_id":"quinidine-sulfate","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quinidine Gluconate","generic_name":"QUINIDINE SULFATE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M2","drug_class":"Antiarrhythmic","quality_score":10,"revenue":null,"mechanism":"Quinidine Gluconate works by blocking the M2 muscarinic acetylcholine receptor, which helps regulate heart rhythm."},{"drug_id":"adenosine","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adenocard","generic_name":"ADENOSINE","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Adenosine receptor A3","drug_class":"Adenosine Receptor Agonist [EPC]","quality_score":43,"revenue":null,"mechanism":""},{"drug_id":"flecainide","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"flecainide","indication_name":"Prevention of Paroxysmal Supraventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"esmolol","indication_name":"Perioperative Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brevibloc In Plastic Container","generic_name":"ESMOLOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":63,"revenue":null,"mechanism":"Brevibloc works by blocking the beta-1 adrenergic receptor, which reduces the heart's response to stress and increases heart rate."},{"drug_id":"esmolol","indication_name":"Supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brevibloc In Plastic Container","generic_name":"ESMOLOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":63,"revenue":null,"mechanism":"Brevibloc works by blocking the beta-1 adrenergic receptor, which reduces the heart's response to stress and increases heart rate."},{"drug_id":"verapamil-hydrochloride","indication_name":"Prophylaxis of repetitive paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"non-interventional-study","indication_name":"Atrial Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"non-interventional-study","indication_name":"Paroxysmal Supraventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"non-interventional-study","indication_name":"Supraventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"non-interventional-study","indication_name":"Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"non-interventional-study","indication_name":"Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"verapamil","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isoptin","generic_name":"VERAPAMIL","company_name":"","drug_phase":"marketed","molecular_target":"Voltage-dependent L-type calcium channel subunit alpha-1C","drug_class":"Calcium Channel Blocker","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"verapamil","indication_name":"Prevention of Paroxysmal Supraventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isoptin","generic_name":"VERAPAMIL","company_name":"","drug_phase":"marketed","molecular_target":"Voltage-dependent L-type calcium channel subunit alpha-1C","drug_class":"Calcium Channel Blocker","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"brevibloc","indication_name":"Perioperative Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Brevibloc","company_name":"AOP Orphan Pharmaceuticals AG","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"brevibloc","indication_name":"Supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Brevibloc","company_name":"AOP Orphan Pharmaceuticals AG","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"sotalol","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betapace","generic_name":"sotalol","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Potassium voltage-gated channel subfamily H member 2","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"procaine","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isocain","generic_name":"PROCAINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A","drug_class":"Amide Local Anesthetic [EPC]","quality_score":34,"revenue":null,"mechanism":""},{"drug_id":"diltiazem","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cardizem","generic_name":"diltiazem","company_name":"Generic (originally Tanabe Seiyaku)","drug_phase":"marketed","molecular_target":"Voltage-dependent calcium channel gamma-1 subunit, Multidrug resistance protein 1, Solute carrier family 22 member 1","drug_class":"Calcium channel blocker (non-dihydropyridine, benzothiazepine)","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"landiolol","indication_name":"Hemodynamically unstable ventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onoact","generic_name":"LANDIOLOL","company_name":"Aop Hlth Us","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"landiolol","quality_score":37,"revenue":null,"mechanism":"Onoact works by blocking the beta-1 adrenergic receptor, which helps to slow down abnormal heart rhythms."},{"drug_id":"landiolol","indication_name":"Sinus tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onoact","generic_name":"LANDIOLOL","company_name":"Aop Hlth Us","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"landiolol","quality_score":37,"revenue":null,"mechanism":"Onoact works by blocking the beta-1 adrenergic receptor, which helps to slow down abnormal heart rhythms."},{"drug_id":"landiolol","indication_name":"Supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onoact","generic_name":"LANDIOLOL","company_name":"Aop Hlth Us","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"landiolol","quality_score":37,"revenue":null,"mechanism":"Onoact works by blocking the beta-1 adrenergic receptor, which helps to slow down abnormal heart rhythms."},{"drug_id":"propranolol","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inderal","generic_name":"propranolol","company_name":"Generic (originally ICI/AstraZeneca)","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2","drug_class":"Non-selective beta-blocker","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"propranolol","indication_name":"Supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inderal","generic_name":"propranolol","company_name":"Generic (originally ICI/AstraZeneca)","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2","drug_class":"Non-selective beta-blocker","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"norpace","indication_name":"Sustained ventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norpace Cr","generic_name":"Disopyramide Phosphate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"G protein-activated inward rectifier potassium channel 4","drug_class":"High Risk QT Prolonging Agents","quality_score":10,"revenue":null,"mechanism":"Norpace is a sodium channel blocker and a Class 1a anti-arrhythmic agent."},{"drug_id":"ganciclovir","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"methoxamine","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methoxamin","generic_name":"METHOXAMINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor","drug_class":"methoxamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"adenosin","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adenosin","company_name":"University of Roma La Sapienza","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 4-kinase type 2-alpha, Phosphatidylinositol 4-kinase type 2-beta, Adenosine kinase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":36,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05741112","title":"The Long COVID-19 Wearable Device Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":100500,"lead_sponsor_name":"Scripps Translational Science Institute","has_results":false},{"nct_id":"NCT06607471","title":"Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Scientific Institute San Raffaele","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT04189822","title":"Hearts in Rhythm Organization (HiRO)National Registry and Bio Bank","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT06324682","title":"ConTempoRary Cardiac Stimulation in Clinical practicE: lEft, BivEntriculAr, Right, and conDuction System Pacing","phase":"","overall_status":"RECRUITING","enrollment_count":8400,"lead_sponsor_name":"University Hospital of Ferrara","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT05521451","title":"Clinical Cohort Study - TRUST","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT04919902","title":"Prague Registry of Electric Cardioversion","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Institute for Clinical and Experimental Medicine","has_results":false},{"nct_id":"NCT05903313","title":"A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software","phase":"","overall_status":"UNKNOWN","enrollment_count":4306,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT05835791","title":"END - VT Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":2454,"lead_sponsor_name":"Nova Scotia Health Authority","has_results":false},{"nct_id":"NCT04496518","title":"Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2200,"lead_sponsor_name":"Medtronic","has_results":false},{"nct_id":"NCT03853369","title":"Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Sichuan Baili Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06269692","title":"MAgnetic Resonance Imaging-guided implanTation of Cardioverter DEFibrillators","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1812,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT03243604","title":"cARdiotoxicity Profile of aBIraTeRone in prostAte Cancer : a pharmacoviGilancE Study","phase":"","overall_status":"COMPLETED","enrollment_count":1717,"lead_sponsor_name":"Groupe Hospitalier Pitie-Salpetriere","has_results":false},{"nct_id":"NCT07149701","title":"Ventricular Tachycardia Cohort","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT04075084","title":"Observation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs)","phase":"","overall_status":"RECRUITING","enrollment_count":1400,"lead_sponsor_name":"Biotronik SE & Co. KG","has_results":false},{"nct_id":"NCT06077799","title":"prehospItal maNagement oF paroxysmaL supraventrICular Tachycardia","phase":"","overall_status":"COMPLETED","enrollment_count":1234,"lead_sponsor_name":"Azienda Usl di Bologna","has_results":false},{"nct_id":"NCT03833089","title":"Targeted Potassium Levels for Prevention of ICD Therapy","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT02433379","title":"Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction","phase":"NA","overall_status":"COMPLETED","enrollment_count":1173,"lead_sponsor_name":"Boston Scientific Corporation","has_results":true},{"nct_id":"NCT04072835","title":"Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1116,"lead_sponsor_name":"Milestone Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT01722942","title":"Amiodarone Against ICD Therapy in Chagas Cardiomyopathy for Primary Prevention of Death","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1100,"lead_sponsor_name":"InCor Heart Institute","has_results":false},{"nct_id":"NCT03464019","title":"Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1097,"lead_sponsor_name":"Milestone Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT04124237","title":"Long Term Monitoring for Risk of Sudden Death","phase":"","overall_status":"COMPLETED","enrollment_count":1051,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT07239804","title":"Systematic Assessment of Treatment Effectiveness for Long-Term Management of Stable Atrial Tachycardia in Inpatient and Outpatient Environments","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Evangelical Hospital Düsseldorf","has_results":false},{"nct_id":"NCT07196397","title":"POLish Registry of CArdioneuroablation and CArdioneuromodulation","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"SABAMED Medical Center Ltd.","has_results":false},{"nct_id":"NCT05061862","title":"Cardiac Implantable Electronic Device (CIED) Research Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Medtronic Cardiac Rhythm and Heart Failure","has_results":false},{"nct_id":"NCT06048731","title":"Enlighten Study: The EV-ICD Post Approval Registry","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Medtronic","has_results":false},{"nct_id":"NCT04599439","title":"CMR Based Prediction of Ventricular Tachycardia Events in Healed Myocardial Infarction (DEVELOP-VT)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Centro Medico Teknon","has_results":false},{"nct_id":"NCT07393009","title":"Studying Routine Patient Care With BIOTRONIK Devices That Allow a More Natural Heart Stimulation","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Biotronik SE & Co. KG","has_results":false},{"nct_id":"NCT07196176","title":"Electrophysiological Registry Duesseldorf","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Heinrich-Heine University, Duesseldorf","has_results":false},{"nct_id":"NCT07491978","title":"Development and Multicenter Validation of an AI-Based Remote Photoplethysmography (rPPG) Facial Scan for Multimodal Health Assessment","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Tarumanagara University","has_results":false},{"nct_id":"NCT03719040","title":"Physiologic Pacing Registry","phase":"","overall_status":"COMPLETED","enrollment_count":870,"lead_sponsor_name":"Abbott Medical Devices","has_results":true},{"nct_id":"NCT03957824","title":"PREVENTION-ACHD Risk Score","phase":"","overall_status":"COMPLETED","enrollment_count":783,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT03855826","title":"Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":756,"lead_sponsor_name":"Sichuan Baili Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06046352","title":"Symptom Burden Guiding Invasive Electrophysiological Study in Paroxysmal Supraventricular Tachycardia","phase":"","overall_status":"COMPLETED","enrollment_count":711,"lead_sponsor_name":"Hospital Universitario 12 de Octubre","has_results":false},{"nct_id":"NCT02863666","title":"Verification of Prediction Algorithm","phase":"","overall_status":"COMPLETED","enrollment_count":673,"lead_sponsor_name":"Zoll Medical Corporation","has_results":true},{"nct_id":"NCT06546137","title":"National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Hospital do Coracao","has_results":false},{"nct_id":"NCT06072287","title":"The Living With a Long-Term Condition Study","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"King's College London","has_results":false},{"nct_id":"NCT03490201","title":"FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":592,"lead_sponsor_name":"Abbott Medical Devices","has_results":false},{"nct_id":"NCT01594112","title":"Ability of Home Monitoring® to Detect and Manage the Inappropriate Diagnoses in Implantable Cardioverter Defibrillators.","phase":"","overall_status":"COMPLETED","enrollment_count":512,"lead_sponsor_name":"Biotronik SE & Co. KG","has_results":false},{"nct_id":"NCT05410860","title":"Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Corxel Pharmaceuticals","has_results":false},{"nct_id":"NCT07109141","title":"Registry of Atrial Arrhythmia Ablation Procedures Using Pulsed Field Ablation in Poland","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Wroclaw Medical University","has_results":false},{"nct_id":"NCT05720936","title":"In-hospital Stellate Ganglion Block for Arrhythmic Storm","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT03963271","title":"Noninvasive Electrocardiographic Imaging for Individuals at Risk for Apparently Idiopathic Ventricular Fibrillation.","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT03231826","title":"Arrhythmias in Post-Myocardial Infarction Patients","phase":"","overall_status":"COMPLETED","enrollment_count":445,"lead_sponsor_name":"Tampere University","has_results":false},{"nct_id":"NCT06573853","title":"Outcomes of PFA Vs. RFA for Patients with PSVT: a Retrospective and Propensity Score Matching Study","phase":"","overall_status":"RECRUITING","enrollment_count":428,"lead_sponsor_name":"Caijie Shen","has_results":false},{"nct_id":"NCT00776087","title":"European Health Economic Trial on Home Monitoring in ICD and CRT-D Patients (EuroEco)","phase":"NA","overall_status":"TERMINATED","enrollment_count":409,"lead_sponsor_name":"Biotronik SE & Co. KG","has_results":false},{"nct_id":"NCT04060680","title":"Extravascular ICD Pivotal Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":393,"lead_sponsor_name":"Medtronic Cardiac Rhythm and Heart Failure","has_results":true},{"nct_id":"NCT03733392","title":"Advisor HD Grid Observational Study","phase":"","overall_status":"COMPLETED","enrollment_count":379,"lead_sponsor_name":"Abbott Medical Devices","has_results":true},{"nct_id":"NCT06931821","title":"Functional ElectroAnatomiC Isochronal Late Activation Mapping for Empiric VT Ablation Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":360,"lead_sponsor_name":"University of Arizona","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}